Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.
about
Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implicationsMechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and goutUse of febuxostat in the management of gout in the United Kingdom.Urate-lowering therapy: current options and future prospects for elderly patients with gout.Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout.New and emerging biomarkers in cardiovascular disease.Febuxostat for the chronic management of hyperuricemia in patients with gout.Management of Gout and Hyperuricemia in CKD.Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 3: Treatment.Odense Pharmacoepidemiological Database: A Review of Use and Content.Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.Gout: An old disease in new perspective - A review.A novel drug management system in the Febuxostat versus Allopurinol Streamlined Trial: A description of a pharmacy system designed to supply medications directly to patients within a prospective multicenter randomised clinical trial.Recent pharmacological advances in the management of gout.Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials.The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies.Uric acid is important, but there is something that matters even more: to deliver sacubitril/valsartan to eligible heart failure patients.
P2860
Q26738948-A254CEA0-09FB-41CE-AA63-74DEDC44EFE2Q27023909-E6E8C1E2-4498-4E1F-8197-BC98EB766AC5Q37649899-CDD45483-AA98-4A91-9828-8AFCBB845521Q38254304-2B39DEFA-89E2-4C27-831E-2A61069F2824Q38365938-479BB714-5C27-4A52-BFC4-F45E2F93ACC5Q38586900-78DFEC86-AF10-454A-9590-A43EA9DCB885Q38760404-AED29D1D-3720-4CAC-8EDB-9987820B9F11Q38812962-4006DCB1-0BF5-4DD1-A4FE-CB6C1C0B218DQ38853112-F8097CF6-24F3-45F7-8860-696CD1DB17C3Q38936565-9762D85D-2E0E-4120-955D-E131FB77A97EQ38977470-5765F056-E5EE-46F8-81CA-CBBD841BDDA4Q39278948-E87D32D8-7746-4C8B-A480-AC91D4F8E742Q40106739-EF6460FE-BD19-488B-AA5E-C444EAB6C48DQ47753935-CC2C296F-1444-4499-A963-8B9C8BA5DE2CQ47919692-C80984F5-0B48-476A-96C7-2A987370D59AQ49584618-26374996-0251-47C8-B2C7-DC5D1DD72341Q49793137-9F6F03AF-D4C7-41D6-8356-F16A4E956F6EQ50071139-CE9D5B5D-DD4E-4C97-A768-0054902D03DA
P2860
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Protocol of the Febuxostat ver ...... of symptomatic hyperuricaemia.
@ast
Protocol of the Febuxostat ver ...... of symptomatic hyperuricaemia.
@en
type
label
Protocol of the Febuxostat ver ...... of symptomatic hyperuricaemia.
@ast
Protocol of the Febuxostat ver ...... of symptomatic hyperuricaemia.
@en
prefLabel
Protocol of the Febuxostat ver ...... of symptomatic hyperuricaemia.
@ast
Protocol of the Febuxostat ver ...... of symptomatic hyperuricaemia.
@en
P2093
P2860
P50
P1433
P1476
Protocol of the Febuxostat ver ...... of symptomatic hyperuricaemia.
@en
P2093
Christopher J Hawkey
Claudine G Jennings
Evelyn Findlay
Fernando Perez Ruiz
George Nuki
John Webster
Matthew Walters
Members of the FAST Study Group
Raffaele De Caterina
P2860
P304
P356
10.1136/BMJOPEN-2014-005354
P577
2014-07-10T00:00:00Z